exRNAdisease

Entry Detail

---



General Information

Database ID: exR0083934 RNA Name: UBE2D3 RNA Type: mRNA Chromosome: chr4 Starnd: - Coordinate: Start Site(bp): 102794383 End Site(bp): 102868896 External Links: ENSG00000109332

Disease Information

Disease Name: Fragile X Syndrome Disease Category: Congenital, Hereditary, and Neonatal Diseases and Abnormalities MeSH ID: D005600 Type: Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities Alias: Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA

Expression Detail

GEO ID: GSE83556 Description: Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions Experimental Design: Disease vs Control Case Disease Type: Fragile X Syndrome Case Disease SubType: NA Case Sample: Fragile X Syndrome Control Sample: Normal Number of Case: 22 Number of Control: 18 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand AATF chr17 36948954 37056871 + ABCB7 chrX 75051048 75156732 - AC010422.3 chr19 12643831 12648397 - AC017083.3 chr2 68131238 68261230 - AC022384.1 chr3 10249372 10285796 + AC084337.2 chr11 6481485 6508978 + AC092143.1 chr16 89919165 89936092 + ACACA chr17 37084992 37406836 - ACSL3 chr2 222860942 222944639 + ACTB chr7 5527148 5563784 - ACTR3 chr2 113890063 113962596 + ACTR6 chr12 100199122 100241865 + ACYP1 chr14 75053237 75069483 - ADD3 chr10 109996368 110135565 + ADGRV1 chr5 90529344 91164437 + AGL chr1 99850361 99924023 + AHCYL1 chr1 109984765 110023742 + AHSA1 chr14 77457870 77469472 + AIF1L chr9 131096476 131123152 + AK4 chr1 65147549 65232145 + AKIRIN2 chr6 87674860 87702233 - AKR1A1 chr1 45550543 45570049 + ALDOA chr16 30064164 30070457 + miRNA targets: NA circRNA targets: NA lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC009133.5 chr16 29808679 29812227 + AC020663.1 chr16 4730115 4752565 - AL117378.1 chr6 131901963 131920565 + Display:

Experiment Detail

GEO ID: GSE83556 Sample Source: Amniotic Fluid Source Fraction: Supernatant Platform: GPL570 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 17063 Sample treatment protocol: RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min). RNA Extract protocol: All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water. RNA library preparation protocol: RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).

Reference

PMID: NA Title: NA Author: NA Journal: NA Description: NA